Role of Volatile Anesthetics for Hepatic Protection

This study has been completed.
Sponsor:
Information provided by:
University of Zurich
ClinicalTrials.gov Identifier:
NCT00516711
First received: August 14, 2007
Last updated: September 14, 2010
Last verified: August 2007

August 14, 2007
September 14, 2010
March 2006
December 2007   (final data collection date for primary outcome measure)
Blood levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT)
Same as current
Complete list of historical versions of study NCT00516711 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Role of Volatile Anesthetics for Hepatic Protection
Role of Volatile Anesthetics for Hepatic Protection in Ischemia-reperfusion

This study aims to evaluate the attenuation of ischemic-reperfusion injury in the liver after sevoflurane preconditioning. In the presence of sevoflurane, an attenuation of liver injury is hypothesized (diminished increase of liver enzymes, reduced production of inflammatory mediators).

Organ protection; preconditioning; volatile anesthetics; ischemia reperfusion

Interventional
Not Provided
Allocation: Randomized
Endpoint Classification: Pharmacodynamics Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Reperfusion Injury
Drug: Sevoflurane
Not Provided
Beck-Schimmer B, Breitenstein S, Urech S, De Conno E, Wittlinger M, Puhan M, Jochum W, Spahn DR, Graf R, Clavien PA. A randomized controlled trial on pharmacological preconditioning in liver surgery using a volatile anesthetic. Ann Surg. 2008 Dec;248(6):909-18.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
December 2007
December 2007   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Older than 18 years of age
  • Patients undergoing liver resection (benign or malignant tumors)

Exclusion Criteria:

  • Laparoscopic liver resection coagulopathy (platelets < 50,000/ml, Quick < 50%)
  • Liver cirrhosis
Both
18 Years to 75 Years
Yes
Contact information is only displayed when the study is recruiting subjects
Switzerland
 
NCT00516711
StV 5-2006
No
Not Provided
University of Zurich
Not Provided
Study Director: 01 Studienregister MasterAdmins UniversitaetsSpital Zuerich
University of Zurich
August 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP